2025

08-Oct-25

Convatec announces closing of $500 Million 5.300% Senior Notes due 2035

02-Oct-25

Convatec announces pricing of $500 Million 5.300% Senior Notes due 2035

01-Oct-25

Convatec announces plans to invest more than $1 billion in R&D facilities – major expansions in the US and UK

29-Sep-25

Convatec announces offering of Senior Notes

22-Sep-25

Convatec secures regulatory approval for ConvaMatrix™ in UK and Europe, supporting more patients with pioneering skin substitute technology

02-Sep-25

Convatec strengthens Leadership Team to support growth

20-Aug-25

Convatec commences share buyback programme

04-Aug-25

Update regarding Chief Executive Officer

29-Jul-25

Interim results for the six months ended 30 June 2025

24-Jul-25

Convatec secures US and European regulatory clearance for Aquacel™ ConvaFiber™ wound care innovation

15-Jul-25

Convatec responds to CMS draft payment proposal for skin substitutes in the United States

01-Jul-25

Comment on CMS proposed rule change issued 30 June 2025

26-Jun-25

Convatec welcomes regulatory approval of subcutaneous apomorphine infusion for advanced Parkinson’s disease in the US

22-May-25

AGM trading update for the four months ended 30 April 2025

20-May-25

Advancing subcutaneous infusion therapy for patients through innovation and partnerships

25-Apr-25

Convatec receives regulatory approval for ConvaNiox™